Akebia Therapeutics (AKBA) Reports Full Enrollment of Phase 3 INNO2VATE Studies; Announces Key Executive Appointments
Tweet Send to a Friend
Akebia Therapeutics, Inc. (NASDAQ: AKBA) today announced full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, that it ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
